GlassScriptPhysician profile
Zachary Solomon
NPI 1861954398
$4,380.45
in general payments reported to CMS, 2019-2025
18 companies · $39.86 in 2025
The $39.86 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.60 · 2020: $68.84 · 2021: $847 · 2022: $1,809 · 2023: $1,124 · 2024: $479 · 2025: $39.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Travel and Lodging: $9.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.73 |
| Travel and Lodging | $9.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.26 | 2020-2024 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $612.25 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $533.66 | 2020-2023 | |
| Janssen Biotech, INC. | $220.80 | 2021-2024 | Tremfya |
| Vyne Pharmaceuticals INC. | $219.45 | 2021 | |
| Ucb, INC. | $203.46 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $167.03 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $133.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Spevigo |
| Kyowa Kirin, INC. | $109.11 | 2022 | |
| Sun Pharmaceutical Industries INC. | $104.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $96.43 | 2022 | |
| Galderma Laboratories, L.P. | $36.36 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $30.00 | 2022 | |
| Incyte Corporation | $24.69 | 2024 | Opzelura |
| Amgen INC. | $20.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.